programs
Precision Immunotherapy Programs
Built Around The Individual Patient
ODI-2001 is designed to translate tumor-specific data into personalized immunotherapy strategies targeting aggressive and treatment-resistant cancers.
programs
Precision Immunotherapy Programs
Built Around The Individual Patient
ODI-2001 is designed to translate tumor-specific data into personalized immunotherapy strategies targeting aggressive and treatment-resistant cancers.
The unmet need
80%
of cancer patients do not respond
to current immunotherapy approaches.
The platform
ODI-2001
A personalized immunotherapy platform designed to activate the immune system against patient-specific neoantigens through AI-assisted selection, synthetic DNA engineering and immune activation.
The unmet need
80%
of cancer patients do not respond to current immunotherapy approaches.
The platform
ODI-2001
A personalized immunotherapy platform designed to activate the immune system against patient-specific neoantigens through AI-assisted selection, synthetic DNA engineering and immune activation.
Every tumor is genetically unique.
Every treatment should be too.
Designed to translate biological complexity
into personalized therapeutic strategies.
Every tumor is genetically unique.
Every treatment should be too.
Designed to translate biological complexity
into personalized therapeutic strategies.
BUILT FOR
Clinical Translation
———
ODI-2001 is engineered from data to delivery with a focus on clinical reality, personalization, and scalability.
BUILT FOR
Clinical Translation
———
ODI-2001 is engineered from data to delivery with a focus on clinical reality, personalization, and scalability.
AI-Assisted Selection
———
Personalized Manufacturing
———
Scalable Platform
———
AI-Assisted Selection
———
Personalized Manufacturing
———
Scalable Platform
———
Initial therapeutic focus
——————————————————
Current treatments leave most patients behind.
Designed for treatment-resistant tumors.
Each tumor is genetically unique. Standard-of-care therapies — from surgery and chemotherapy to checkpoint inhibitors — treat cancer broadly. Odimma treats the tumor as it actually is: specific to the patient.
ODI-2001 has demonstrated strong anti-tumor activity across several pre-clinical aggressive and treatment-resistant cancer models, including melanoma, colorectal and breast cancer.
By combining personalized synthetic DNA technology, immune modulation and advanced neoantigen targeting, the platform is engineered to enhance the efficacy of immunotherapy approaches in solid tumors.
Initial therapeutic focus
——————————————————
Current treatments leave most patients behind.
Designed for treatment-resistant tumors.
Each tumor is genetically unique. Standard-of-care therapies — from surgery and chemotherapy to checkpoint inhibitors — treat cancer broadly. Odimma treats the tumor as it actually is: specific to the patient.
ODI-2001 has demonstrated strong anti-tumor activity across several pre-clinical aggressive and treatment-resistant cancer models, including melanoma, colorectal and breast cancer.
By combining personalized synthetic DNA technology, immune modulation and advanced neoantigen targeting, the platform is engineered to enhance the efficacy of immunotherapy approaches in solid tumors.
treatment-resistant cancers
Focusing on Cancers with High Unmet Need
treatment-resistant cancers
Focusing on Cancers with High Unmet Need
Every tumor carries
a different biological story.
ODI-2001 is designed to respond to it.
By combining genomic analysis, AI-assisted target identification and synthetic DNA engineering, the Odimma platform is designed to support personalized therapeutic strategies across multiple clinical settings.
Every tumor carries
a different biological story.
ODI-2001 is designed to respond to it.
By combining genomic analysis, AI-assisted target identification and synthetic DNA engineering, the Odimma platform is designed to support personalized therapeutic strategies across multiple clinical settings.